发明名称 |
AKT TYROSINE 176 PHOSPHORYLATION CANCER BIOMARKER |
摘要 |
AKT/PKB kinase is a key signaling component of one of the most frequently activated pathways in cancer and is a major target of cancer drug development. The present study uncovered that growth factors binding to RTKs lead to activation of a non-receptor tyrosine kinase, Ack1 (TNK2), which directly phosphorylates AKT at a conserved tyrosine 176 residue. Tyr176-phosphorylated AKT binds to phosphatidic acid and localizes to the plasma membrane, leading to AKT activation. Expression levels of Tyr176-phosphorylated-AKT and Tyr284-phosphorylated-Ack1 were positively correlated with the severity of disease progression, and inversely correlated with the survival of breast, prostate, lung and pancreatic cancer patients. |
申请公布号 |
US2012053225(A1) |
申请公布日期 |
2012.03.01 |
申请号 |
US201113205171 |
申请日期 |
2011.08.08 |
申请人 |
MAHAJAN NUPAM P.;MAHAJAN KIRAN N.;H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
发明人 |
MAHAJAN NUPAM P.;MAHAJAN KIRAN N. |
分类号 |
A61K31/713;A61K31/7088;A61P35/00;C07K16/00;C12Q1/48;C12Q1/68;C40B30/04 |
主分类号 |
A61K31/713 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|